Herpes simplex virus 1 (HSV) is a ubiquitous human virus resident in a majority of the global 33 population as a latent infection. Acyclovir (ACV), is the standard of care drug used to treat primary 34 and recurrent infections, supplemented in some patients with intravenous immunoglobulin (IVIG) 35 treatment to suppress deleterious inflammatory responses. We found that HSV, ACV and IVIG 36 can all independently disrupt the gut bacterial community in a sex biased manner when given to 37 uninfected mice. Treatment of HSV infected mice with ACV or IVIG alone or together revealed 38 complex interactions between these drugs and infection that caused pronounced sex biased 39 dysbiosis. ACV reduced Bacteroidetes levels in male but not female mice, while levels of the 40 Anti-inflammatory Clostridia (AIC) were reduced in female but not male mice, which is significant 41 as these taxa are associated with protection against the development of GVHD in hematopoietic 42 stem cell transplant (HSCT) patients. Gut barrier dysfunction is associated with GVHD in HSCT 43 patients and ACV also decreased Akkermansia muciniphila, which is important for maintaining 44 gut barrier functionality. Cumulatively, our data suggest that long-term prophylactic ACV treatment 45 of HSCT patients may contribute to GVHD and potentially impact immune reconstitution. These 46 data have important implications for other clinical settings, including HSV eye disease and genital 47 infections, where ACV is given long-term. 48 49 Author Summary. 50 51 Primary and reactivated HSV and VZV infections are treated with Acyclovir (ACV), an 52 antiviral drug that blocks viral DNA synthesis. In some patients IVIG is used as adjunctive therapy 53 to block deleterious inflammation. Long term preventative treatment of patients who receive stem 54 transplants for various blood cancers has been successful in preventing life threatening 55 reactivated HSV and VZV infections, but GVHD remains a major factor limiting transplant 56 3 success. Studies reported here reveal that HSV infection, ACV and IVIG given alone can all 57 disrupt the gut microbiota and that complex interactions between these drugs and infection results 58 in even more pronounced sex biased changes in the gut bacteria community structure. 59 Importantly, ACV treatment decreased the levels of specific bacterial taxa, including the anti-60 inflammatory Clostriodia and Bacteroidetes that have been shown to protect against development 61 of GVHD in stem cell transplant patients. These data suggest that long term preventative 62 treatment of patients with ACV may contribute to GVHD in transplant patients and have negative 63 consequences in other HSV induced diseases treated long term with ACV. The health effects of 64 long term ACV and IVIG treatments warrant further clinical studies. 65 66 Introduction. 67 68 Herpes Simplex Virus type 1 (HSV), a ubiquitous human virus is the major cause of HSV 69 encephalitis (HSE), the most prevalent sporadic encephalitis resulting from either primary 70 infection or reactivation of latent virus. However, despite improved diagnostic procedures and 71 effective antiviral therapies, most HSE survivors have persistent neurological impairments, 72
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Treating HSV infected mice with ACV from day 4 pi for three days resulted in even more 133 drastic shifts in the gut bacteria composition and exaggerated sex differences (Figure 2A) , than 134 for infection alone. Considerable abundance changes were evident at the Phyla level for 135
Bacteroidetes, Firmicutes and Verrucomicrobia (Figure 2B) and at the species level (Figure 2C) . 136
Notably, whereas HSV infection reduced the abundance of Firmicutes significantly in male but 137 not female mice (Figure 1B) , ACV reversed this effect restoring the abundance to the level in 138 uninfected male mice, while also increasing the abundance in female mice (Figure 2B and Figure  139 1B). Notable abundance changes at the species level included drastic suppression of Clostridium 140 aerotolerans in infected male mice compared to increased abundance in females (Figure 1C) , 141 while ACV treatment further increased this abundance only in females (Figure 2C) . Akkermansia 142 muciniphila abundance was increased by infection in male mice but reduced in females ( Figure  143 1C), while ACV treatment resulted in total suppression of this species in female mice compared 144 to a marked reduction in male mice (Figure 2C ). There are many other similar changes in species 145 abundance that are differentially impacted by ACV treatment in a sex-biased manner, indicative 146 of complex interactions between infection, ACV effects on infected host cells, and bacteria, as 147 well as metabolites produced by bacterial metabolism of ACV. 148 149 Treatment of uninfected mice with IVIG alone also shifted the gut bacteria community 150 composition with a notable marked sex effect as determined by a beta diversity analysis ( Figure  151 3). Males and females showed a major reduction in A. muciniphila, and a lesser reduction of 152 Verrucomicrobia in males, compared to females that showed increased abundance of this phylum 153 in response to IVIG treatment (Figure 4) . The abundance of many other bacterial species was 154 differentially altered by IVIG treatment of males and females, for example, Clostridium 155 aerotolerans, Bacteroides acidifaciens and Porphyromonadaceae (Figure 4B) . The response to 156 IVIG was distinct in HSV infected mice, and the complex interactions between infection, ACV and 157 IVIG were also evident at the phyla and species levels and were strongly sex biased as well 158 7 ( Figure 4A and 4B) . IVIG treatment decreased A. muciniphila abundance markedly in infected 159 males and females as did ACV, whereas in contrast, treatment with ACV+IVIG caused a notable 160 increase in its abundance, indicative of antagonistic effects of these two drugs in the context of 161 infection (Figure 4B) In a similar vein, C. aerotolerans abundance increased markedly in males, 162 but was unchanged in females treated with IVIG, while in contrast, it was strongly decreased in 163 males but slightly increased in females treated with ACV alone. In contrast, treatment with 164 ACV+IVIG suppressed an IVIG-induced increase in males and an ACV-induced increase in 165 females, revealing antagonism between ACV and IVIG in the context of HSV infection ( Figure  166 4B). 167
168
Patients with hematologic and other malignancies have benefited immensely from 169 allogeneic hematopoietic stem cell transplantation (allo-HSCT or HSCT), which can be a potent 170 curative immunotherapy. However, life threatening complications such as graft-versus-host 171 disease (GVHD), relapse, and infections that include reactivated HSV and VZV limit its application 172 [16] . HSV and varicella zoster (VZV) reactivation has been successfully suppressed by 173 prophylactic ACV treatment, though ACV-resistant (ACVr) HSV is an emerging problem [17, 18] . 174
Long term ACV prophylactic treatment is now routine for HSCT patients, because it was found to 175 correlate with reduced HSV and ACVr HSV disease in those treated for longer than 1 year [19] . 176 177 Given this routine clinical practice, we evaluated the effects of ACV on fecal bacteria, 178 because gut microbes have been implicated in GVHD pathophysiology and because we posit that 179 ACV contributes to the development of GVHD by changing the gut microbiota. First, we identified 180 gut bacterial changes in humans with GVHD [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Next, we determined whether the ACV-181
induced changes that we detected in this mouse study matched those GVHD-associated 182 changes. Whenever we identified taxa that were altered in both types of studies, the direction of 183 the change was the same, and it was consistent with our hypothesis that ACV contributes to the 184 12 289 This study has several limitations. Being exploratory in nature, analyses of the gut bacteria 290 were done at a single time point immediately after infection or drug treatment, rather than as a 291
longitudinal study that would have provided information on the persistence of the dysbiotic state 292 as well as mechanistic insights as to how HSV, ACV and IVIG provoke dysbiosis. Ideally, the 293 effects of ACV should be tested in latently infected mice, since virtually all HSCT patients harbor 294 latent HSV. However, because HSV infection alone disrupts the gut bacterial community, 295 assessing the effects of ACV on the gut bacteria community structure in the latently infected mice 296 would likely be difficult. Because ACV was given ip to mice but usually orally to HSCT patients 297
[67], its effects on the gut bacteria community maybe underestimated in our study. 298
299
Notwithstanding these caveats, our finding that ACV treatment of HSV infected mice 300 decreased the relative abundances of several bacterial taxa is important because these bacteria 301 have been negatively correlated with the induction of and mortality from GVHD in HSCT patients 302 [24, 27, 28, 30] . These results are also consistent with our hypothesis that ACV contributes to the 303 development of GVHD by changing the gut microbiota. In the context of allo-HSCT, GVHD occurs 304 when donor immune cells recognize recipient tissues as foreign, leading to immune-mediated 305 damage to several organs and tissues including the gastrointestinal tract. This has led 306 researchers to posit that the reduction of anti-inflammatory bacteria such as AIC contribute to 307 GVHD pathology [30] . The results from our study extend this hypothesis to include ACV treatment 308 as a putative contributor to GVHD, because ACV reduced AIC bacteria in the gut. ACV treatment 309 also decreased the relative abundances of several members of the Bacteroidetes, some of which 310 have been shown to exhibit anti-inflammatory properties [68] [69] [70] [71] . More relevantly, the capsular 311 polysaccharide A (PSA) from Bacteroides fragilis reduced HSV-associated mortality in mice by 312 dramatically reducing immune-mediated inflammation [72] . In addition, the two most abundant 313
OTUs identified in our study, whose relative abundances were positively (Porphyromonadaceae) 314 13 and negatively (A. muciniphila) correlated with ACV treatment, have been shown to weaken [37, 315 38] and strengthen [39] [40] [41] gut barrier function, respectively. These results provide an additional 316 link between ACV treatment and GVHD, because barrier dysfunction, which can cause systemic 317 inflammation, is a hallmark of GVHD [32] [33] [34] [35] [36] . Finally, long-term ACV prophylaxis initiated early 318 after HSCT might also impair immune reconstitution based on results from a study of antibiotic 319 depletion of gut bacteria in a murine model of syngeneic bone marrow transplantation [73] . These 320 tantalizing results warrant independent validation and further detailed studies using a murine 321 autologous BMT model to more rigorously evaluate the impact of long-term ACV prophylaxis on 322 GVHD and engraftment, because results from such studies might eventually lead to improved 323 outcomes for HSCT patients. Ideally, such future studies should be performed with mice harboring 324 wild microbiota, because several recent reports show that immune responses in mice with wild 325 microbiomes model human immune responses more closely than conventional mice with SPF 326 microbiota [74] [75] [76] . Male and female mice, 6-8 weeks of age, were infected with HSV1 17 + , a virulent strain. Mice 342 were sedated with ketamine (60 mg/kg) and xylazine (5 mg/kg) prior to HSV inoculation by corneal 343 scarification. B6 mice were bilaterally inoculated with 1x 10 5 PFU per eye and monitored daily as 344 previously described [15, 77] . (5) HSV_M (5) NoHSV_F (5) NoHSV_M (5 NoHSV_ACV+IVIG_M (5) NoHSV_ACV+IVIG_F (5) HSV_ACV+IVIG_F (5) HSV_ACV+IVIG_M (5) HSV_IVIG_F (5) HSV_IVIG_M (5) NoHSV_ACV_F (5) NoHSV_ACV_M (5) NoHSV_IVIG_F (5) NoHSV_IVIG_M (5) NoHSV_F (5) NoHSV_M (5) 
